Ignite Creation Date:
2024-05-06 @ 7:29 PM
Last Modification Date:
2024-10-26 @ 3:08 PM
Study NCT ID:
NCT06039683
Status:
COMPLETED
Last Update Posted:
2024-06-27
First Post:
2023-09-06
Brief Title:
A Multicountry Multicentre Non-interventional Retrospective Study to Determine Real-world Treatment Patterns and Associated Outcomes After First Line Osimertinib in Patients With Advanced and Metastatic NSCLC EGFRm in the GCC Region
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A Multicountry Multicentre Non-interventional Retrospective Study to Determine Real-world Treatment Patterns and Associated Outcomes After First Line Osimertinib in Patients With Advanced and Metastatic NSCLC EGFRm in the GCC Region
Status:
COMPLETED
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TREASURE
Brief Summary:
A Multicountry Multicenter Non-interventional Retrospective Study to determine Real-world treatment patterns and associated outcomes after FIRST LINE Osimertinib in patients with advanced and Metastatic NSCLC harboring EGFR-activating mutations in the GCC Region
Detailed Description:
Osimertinib has demonstrated superior PFS compared to firstgeneration EGFR-TKIs erlotinib and gefitinib in the first line setting in clinical trials There remains a need to consider clinical outcomes in the real-world setting and determine the characteristics of long-term survivors in the real world It will also be important to determine the subsequent treatment pathways of patients who progress on treatment with Osimertinib
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None